Psilocybin-Research.comSearchable psilocybin and psilocin bibliometrics.
Published

High dose of psilocybin effective for treatment-resistant depression

Adults with treatment-resistant depression who received a single 25-mg dose of psilocybin saw significant improvement in depressive symptoms relative to a control dose at 3 weeks, a Phase 2b trial has found. A smaller 10-mg dose of psilocybin did not result in significant improvement over the control dose of 1 mg, and adverse events were common in both of the higher-dose groups. Study results were published in the Nov. 3, 2022 issue of The New England Journal of Medicine.

Open source BibTeX RIS

Bibliographic context

Journal
The Brown University Psychopharmacology Update
Date
2022-12-26
Source
OpenAlex
DOI
10.1002/pu.30970
PubMed
Unavailable

Authors

Watch author

Topics and keywords

psilocybin DepressionPharmacologyClinical TrialTreatment-Resistant DepressionAdverse Events Clinical Trial PsilocybinAdverse effectMedicineDepression (economics)Treatment-resistant depressionHallucinogenPharmacologyMajor depressive disorderPsychiatryCognitionEconomicsMacroeconomicsPsychedelics and Drug StudiesDigital Mental Health InterventionsChemical synthesis and alkaloids

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

High dose of psilocybin effective for treatment-resistant depression2022-12-26

Related papers

Psilocybin for Treatment-Resistant Depression: A Comprehensive Review of Mechanisms and Therapeutic PotentialDigital Showcase Research, Scholarship, & Creative Works (University of Lynchburg) · 2026-05-21Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine and Surgery · 2026-06-17Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b TrialPsychotherapy and Psychosomatics · 2026-05-26Rapid-acting interventions in treatment-resistant depression - a comparative review of esketamine and psilocybinJournal of Pre-Clinical and Clinical Research · 2026-05-11Psilocybin-Assisted Therapy in Depressive Disorders: Efficacy, Safety, and Persistence of Clinical Effects - A Narrative ReviewJournal of Education Health and Sport · 2026-05-06Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARASAIMSARA Journal · 2026-06-14Efficacy of Psilocybin-Assisted Therapy in Major Depressive Disorder: A Systematic Review and Meta-AnalysisPsychiatry International · 2026-06-14Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionJournal of Affective Disorders · 2026-06-03